Aetna backs off a colonoscopy change
New York Times, February 28, 2008
Aetna has announced that it had suspended a plan to stop paying for routine use of a powerful anesthetic in a procedure to screen for colon cancer. The drug, propofol, provides quick and reliable sedation for patients who are undergoing a colonoscopy. Critics had said that restricting use of propofol would discourage patients from undergoing a colonoscopy. The American Gastroenterological Association, a medical society representing the doctors who perform colonoscopies, had recommended that Aetna defer its plan and praised the company for the decision.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- 3 Traits Personality Assessments Can't Reveal
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- Carondelet to Pay $35M to Settle Fraud Allegations
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- CHS Hacked, 4.5M Patient Records Compromised